What's Happening?
ONL Therapeutics, a clinical-stage biopharmaceutical company, has announced the completion of enrollment for its global Phase 2 GALAXY trial. The trial, which is evaluating the efficacy and safety of xelafaslatide (formerly ONL1204) for patients with
geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), has enrolled over 324 participants across sites in the U.S., Canada, and Europe. According to David N. Zacks, M.D., Ph.D., chief scientific officer at ONL Therapeutics, the rapid enrollment signifies a strong demand from physicians and patients for new treatment options for GA, an irreversible disease with limited approved therapies. Xelafaslatide is designed to protect retinal cells from Fas-mediated cell death, aiming to preserve vision with a potential dosing frequency of every three to six months. The GALAXY trial builds on positive data from a Phase 1b study, which indicated that xelafaslatide was generally safe and well-tolerated, showing encouraging efficacy signals after six months. The primary endpoint of the trial is the rate of growth of the GA lesion area, assessed at 48 weeks, with additional measurements extending to 72 weeks.
Why It's Important?
The completion of enrollment in ONL Therapeutics' GALAXY trial marks a significant milestone in the development of new treatments for geographic atrophy (GA), a leading cause of vision loss. GA, an advanced form of age-related macular degeneration (AMD), currently has few approved treatments, particularly in Europe, making the need for novel therapies critical. Xelafaslatide's unique mechanism of action, targeting Fas-mediated cell death to protect retinal cells, offers a potentially differentiated approach to preserving vision. If successful, this treatment could significantly reduce the burden on patients by offering less frequent dosing compared to existing therapies, thereby improving quality of life for individuals suffering from this debilitating condition. The global scope of the trial, encompassing sites in the U.S., Canada, and Europe, underscores the widespread impact of GA and the international effort to find effective solutions. Positive results from this trial could lead to a new therapeutic option, offering hope to millions affected by GA and potentially reshaping the treatment landscape for retinal diseases.
What's Next?
With enrollment now complete, ONL Therapeutics will focus on supporting all participants through the study's conclusion. The company anticipates releasing topline data on the 48-week primary endpoint in the fourth quarter of 2027. This data will be crucial in determining the efficacy and safety profile of xelafaslatide and will guide the next steps in its clinical development. If the results are positive, ONL Therapeutics will likely proceed with discussions with regulatory bodies, such as the FDA in the U.S., to advance towards potential market approval. The successful outcome of this Phase 2 trial could pave the way for a Phase 3 study, which is typically the final stage before seeking regulatory approval. The biopharmaceutical community and patients with geographic atrophy will be closely watching for these results, as they could signify a major breakthrough in treating this currently underserved condition.
Beyond the Headlines
The development of xelafaslatide by ONL Therapeutics represents a broader trend in ophthalmology research: the pursuit of therapies that target fundamental cellular pathways of disease progression rather than just managing symptoms. By focusing on Fas-mediated cell death, ONL Therapeutics is addressing a core mechanism of retinal cell degeneration, which could have implications beyond geographic atrophy. This approach highlights the increasing sophistication in drug development, moving towards precision medicine that intervenes at the molecular level. Furthermore, the potential for less frequent dosing (every three to six months) could significantly improve patient adherence and reduce the treatment burden, which is a major challenge in chronic eye conditions requiring frequent injections. This could lead to better real-world outcomes and a higher quality of life for patients, setting a new standard for convenience and effectiveness in retinal disease management. The success of such a therapy could also stimulate further research into similar cell-protective mechanisms for other neurodegenerative conditions affecting the eye.













